Cardiff's questionable plan yields more questions
More data from onvansertib's phase 2 study fail to convince.
Astra’s Neogene investment nosedives
NT-125 is discontinued, while two key Datroway readouts are delayed.
Celcuity's $5m pivot does the job
A Pfizer cast-off could become the company's first marketed drug.
